Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil in Advanced HFrEF
NCT00610051Phase 3Not yet recruiting
- Sponsor
- Biopeutics Co Ltd
- Start
- Oct 2026
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Vasostenoon in heart failure with reduced ejection fraction (HFrEF), sponsored by Biopeutics Co Ltd. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
Vasostenoon
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT00610051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00610051.